mRNA-1273

COVID-19

Two-dose, lipid nanoparticle RNA vaccine

Development status

  1. Emergency use/conditional marketing authorizations granted in multiple countries
  2. Phase I/II trial underway in Japan
26 active deals

Emergency use
authorizations granted in:

Drugs to Watch - mRNA-1273 Placeholder
Drugs to Watch - mRNA-1273

Distribution

The vaccine is well-tolerated, easily distributed, storable at refrigerator temperatures and easily administered.

With a reported 94% efficacy when administered per protocol.

Drugs to Watch 2021

Drugs to Watch
Drugs to Watch
Drugs to Watch
Drugs to Watch
Drugs to Watch
Drugs to Watch

From innovation to bottom line

Access our global intelligence, advanced analytics and global team of experts.

Contact our team